Last reviewed · How we verify

NCT05871450

Legacy of the Special Olympics World Games Berlin 2023

Completed NA Results posted Last updated 28 August 2025
What this trial tests

NA trial testing Inclusive events in Inclusion, Social in 700 participants. Completed in 30 June 2024.

Timeline
1 March 2023
Primary endpoint
31 December 2023
30 June 2024

Quick facts

Lead sponsorGerman University of Health and Sports
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposehealth services research
Enrollment700
Start date1 March 2023
Primary completion31 December 2023
Estimated completion30 June 2024
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

German University of Health and Sports

Who can join

18 and older, any sex, with Inclusion, Social. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Attitudes Measured With the ATTID-Questionnaire Primary · Change from baseline (T1) attitudes toward people with intellectual disability (ATTID-Questionnaire) at 3-4 month (T2) and 8-9 month (T3)

The ATTID-SF Questionnaire encompassing three core components. The affective component refers to emotional responses toward individuals with intellectual disabilities. The cognitive component encompasses beliefs, knowledge, and perceptions about this population. The behavioral component reflects self-reported actions. The short form comprises 35 items rated on a 5-point Likert scale (1 = strongly agree to 5 = strongly disagree), with higher scores indicating more negative attitudes. Items are grouped into five factors: (1) interaction, (2) sensitivity/tenderness, (3) discomfort, (4) knowledge

T1 Discomfort
GroupValue95% CI
Participants Living in Host Towns1.95± 0.77
Participants Not Living in Host Towns2.20± 0.76
T1 Knowledge of capacity and rights
GroupValue95% CI
Participants Living in Host Towns1.78± 0.55
Participants Not Living in Host Towns2.04± 0.55
T1 Interaction
GroupValue95% CI
Participants Living in Host Towns2.22± 0.65
Participants Not Living in Host Towns2.41± 0.71
T1 Sensitivity or tenderness
GroupValue95% CI
Participants Living in Host Towns2.57± 0.95
Participants Not Living in Host Towns2.71± 0.94
T1 Knowledge of causes
GroupValue95% CI
Participants Living in Host Towns1.89± 0.55
Participants Not Living in Host Towns2.07± 0.42
T2 Discomfort
GroupValue95% CI
Participants Living in Host Towns1.92± 0.81
Participants Not Living in Host Towns2.19± 0.76
T2 Knowledge of capacity and rights
GroupValue95% CI
Participants Living in Host Towns1.82± 0.51
Participants Not Living in Host Towns1.99± 0.50
T2 Interaction
GroupValue95% CI
Participants Living in Host Towns2.21± 0.63
Participants Not Living in Host Towns2.45± 0.64

Sponsor's own description

This research aims to evaluate the impact of the project "170 Nations - 170 Inclusive Communities" of the Special Olympics World Games 2023 (SOWG 23) on sustain inclusive structures for people with intellectual disabilities (ID). The research utilizes a quasi-experimental research design and a qualitative research design and will synthesize qualitative and quantitative data to display successful and non-successful interventions for more inclusive communities. The research will target 56 host communities of SOWG 23 and 56 non-host communities, interviewing 200 people with ID and a minimum of 400 key stakeholders, as well as conducting qualitative interviews and focus groups.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05871450.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing